Study to Evaluate Long-term Antibody Persistence of GlaxoSmithKline Biologicals' MenACWY-TT Vaccine (GSK134612) Vs Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

Final Report: A Phase IIIb, Open, Multi-Center Study to Evaluate the Long-Term Antibody Persistence at 6, 7, 8, 9, and 10 Years After the Administration of One Dose of
Meningococcal Conjugate Vaccine MenACWY Versus 1 Dose of Meningococcal Polysaccharide Vaccine Mencevax® ACWY, and to Evaluate the Safety and Immunogenicity of a Booster Dose of MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination
of 11-55 Year Old Subjects With MenACWY-TT or Mencevax® ACWY

Category & Conditions:
Vaccine-related Conditions
Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine) Identifier (NCT):
Protocol ID:
Open Plain Language Summary Result:Click here